Search

Yu Wang,1 Meng Zhang,2,3 Yixin Gong,2 Qiyan Wu,1 Lijun Zhang,1 Shunchang Jiao1 1Department of Oncology, Oncology Faculty, Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Department of Research and Development, Beijing DCTY® Biotech Co.,Ltd, Beijing, People’s Republic of China; 3Department of Hepatobiliary Surgery, PLA Rocket Force Characteristic Medical Center, Beijing, People’s Republic of ChinaCorrespondence: Shunchang JiaoDepartment of Oncology, Oncology Faculty, Chinese PLA General Hospital, Beijing, People’s Republic of ChinaTel +86-1066875308Email jiaosc@vip.sina.comIntroduction: Hepatocellular carcinoma (HCC) continues to be a cancer with rising incidence, high mortality, and recurrence rate. The therapeutic effects on HCC are not satisfactory currently. Epidermal growth factor receptor (EGFR) is an important factor, while anti-EGFR agencies have not shown ideal results in HCC.Materials and Methods: We tested efficacy of nimotuzumab and EGFR expression on cell surface in six HCC cell lines (Hep 3B2.1– 7, Li-7, PLC/PRF/5, SK-HEP-1, SNU-182, and SNU-387). Then, we analyzed RNA sequences of every cell line and performed a bioinformatic analysis. Differentially expressed genes (DEGs) were analyzed. The data, TCGA-LIHC from The Cancer Genome Atlas (TCGA) and GSE102079 from Gene Expression Omnibus (GEO), were used to analyse DEGs of Hoshida subclass.Results: Hep 3B2.1– 7 and PLC/PRF/5 were sensitive to nimotuzumab whereas Li-7, SK-HEP-1, SNU-182, and SNU-387 cell lines were resistant. Then, we compared the DEGs between sensitive and resistant group cell lines. We enriched DEGs in GO and KEGG and performed GSEA in each group. Genes in two groups did not show obvious different expressions in EGFR pathways, while Hoshida subclass of HCC seemed to associate with the efficacy of nimotuzumab in that S2 and S3 showed better therapeutic effect than S1. Therefore, we analyzed genes in hu

As an effective long-term incentive for listed companies, equity options have been proven in some developed countries. Therefore, under the unique national conditions of China and the existing state of the stock market, we cannot blindly introduce the stock option system of developed countries but should strengthen the research on the strike price of equity options of Chinese listed corporations, find the basis of the strike price pricing, and analyze the influencing factors of the strike price pricing. Establishing an exercise price pricing scheme that suits Chinese characteristics and establishing a more scientific option incentive mechanism is a concern for listed corporations in China. The research object is the equity option exercise spread of listed companies, and sample data are collected from 2011 to 2021. This research would break through the previous multiple regression and factor analysis methods, use the econometric software EViews10.0 as a tool and select several representative factors such as the listed companies' characteristics, the financial indicators, the governance structure, and the risk level to analyze the determinants of equity options’ strike price. The data of 123 listed firms with equity option plans in Shanghai and Shenzhen A-shares are tested for correlation and analyzed in a panel data model to study how the various influencing factors affect the strike price. The study also analyses the significance and importance of each element. It concludes to determine the factors listed companies should consider when pricing equity options to propose corresponding policy recommendations for relevant listed companies and government departments.